Alemtuzumab in refractory Sézary syndrome

Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promis...

Descripción completa

Detalles Bibliográficos
Autores principales: Reifs, Carmen María Alcántara, Salido-Vallejo, Rafael, Garnacho-Saucedo, Gloria María, la Corte-Sánchez, Sofía De, González-Menchen, Alberto, García-Nieto, Antonio Vélez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087225/
https://www.ncbi.nlm.nih.gov/pubmed/27828640
http://dx.doi.org/10.1590/abd1806-4841.20164322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087225/
https://www.ncbi.nlm.nih.gov/pubmed/27828640
http://dx.doi.org/10.1590/abd1806-4841.20164322

Ejemplares similares